FDA experts advise stronger warning labels for flu drugs

An FDA panel on Tuesday recommended that Roche change warning labels on influenza drug Tamiflu to include information on the death of several patients who developed psychiatric problems after treatment. The committee also suggested additional warnings about the risk of delirium, hallucinations and psychotic behavior linked to GlaxoSmithKline's Relenza. Roche said it hasn't found evidence that its drug caused such side effects but would continue to study the issue, and Glaxo also said there was no evidence of a link with its drug.

View Full Article in:

Bloomberg1 · NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA